Krystal(KRYS) - 2025 Q4 - Annual Results

Financial Projections - Krystal Biotech expects total net product revenues for VYJUVEK to be between $106 million and $107 million for Q4 2025, and between $388 million and $389 million for the full year 2025[5] - The company's cash, cash equivalents, and investments are expected to be approximately $955 million as of December 31, 2025[5] - The preliminary financial information is unaudited and may change upon completion of the ongoing audit for the year ended December 31, 2025[5] Strategic Vision - The company has outlined its rare disease strategic vision and corporate objectives for 2026 in the press release[5]